Online Inquiry
Small Molecule Drug Conjugate Development Service
Small molecule drug coujugates (SMDCs) are targeted therapies that allow small molecules to act as targeting ligands to selectively release potent cytotoxic agents in the tumor microenvironment. At Alfa Cytology, we are committed to providing one-stop small molecule drug coujugates (SMDCs) development services for prostate cancer.
Introduction to Small Molecule Drug Conjugates
Small molecule drug coujugates (SMDCs) are targeted drugs that selectively release potent cytotoxic drugs in the tumor microenvironment via small molecules acting as targeting ligands. SMDCs offer various advantages in terms of ease of synthesis and storage, homogeneity, and cost-effectiveness in selectively delivering the drug to cancer cells. These make it a great potential in the direction of cancer therapy, especially prostate cancer.
Fig.
1 Small Molecule Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment. (Wang, T., et al.
2024)
Structure of Small Molecule Drug Conjugates
SMDCs are derived from the coupling of a small-molecule targeting ligand with a cytotoxic drug and consists of four components, including a targeting ligand, s spacer, a cleavable bridge, and a therapeutic payload. The design of the components of a small molecule drug can greatly affect the drug effect of the conjugate and also the metabolic process of the drug in the body.
Fig. 2 Structure of the SMDC. (Wang, T.,
et al. 2024)
- Selection of Ligands
To prevent impacting drug accumulation and content at the tumor site, the size of SMDC must be suitable. Promising applications include folic acid derivatives for folate receptor targeting, glutaraldehyde derivatives for prostate-specific membrane antigen targeting, and so on.
- Selection of Payload
The choice of payload is essentially the same as that required for ADC, and the cytotoxic molecules used are also essentially the same, such as medenosine, khakimycin, and so on.
- Selection of Linker
In SMDC, linkers are typically breakable due to the rapid binding to receptors and clearance by the kidneys within minutes to an hour. This means the linker doesn't need to be very stable, just enough to last for a few minutes to an hour.
Small Molecule Drug Conjugates Development for Prostate Cancer
Small molecule drug coujugates (SMDCs) are a promising approach to targeted therapy, greatly enhancing the therapeutic potential of anticancer drugs. Many clinical small molecule coupling drugs have been developed for various tumors, but fewer are currently available for prostate cancer.
| Compound | Targeting Ligand | Payload | Linker | Company |
| EC-1169 | L-Glu-urea-L-Lys | Tubulysin B hydrazide | Disulfide bond | Novartis |
Our Services
At Alfa Cytology, we continuously focus on small molecule drug coujugates (SMDCs) research in the field of prostate cancer, aiming to provide comprehensive development services customized to our customers' needs. Our key differentiator is our ability to plan and execute complex development tasks on time, saving our clients development time and costs. As a highly recognized pioneer in the global therapeutic antibody field, we have professional knowledge and extensive experience.
Targeting Ligand Screening
In terms of efficient design of SMDCs, we fully consider the properties of SMDCs to achieve the desired pharmacokinetic properties of SMDCs.
Linker Design and Synthesis
To keep the SMDCs effective, we selected suitable spacers and cleavable bridges based on the types of targeting agents and treatments to adjust their binding and therapeutic properties.
Selection of Payload
The selection of therapeutic small molecule payloads plays a crucial role in clinical evaluation, and we provide a wide range of modified payload development services covering a variety of apoptotic or lysis mechanisms.
One-stop Solutions for Small Molecule Drug Coujugates Development
Alfa Cytology provides one-stop SMDCs development services tailored specifically for prostate cancer.
Nowadays, small molecule drug coujugates (SMDCs) have become an important research direction in prostate cancer therapy, and more innovative SMDCs may be applied in the therapy of prostate cancer in the future. We provide one-stop service for small molecule drug coujugates (SMDCs) development. Contact us to learn more about our services.
Reference
- Wang, T., et al. Small Molecule-Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment. Molecular pharmaceutics. 2024, 21(3): 1038-1055.
For research use only.